Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Eli Lilly and Companys #Retatrutide Delivers Up to 28.3% #Weight #Loss While Simultaneously #Improving #Diabetes, #Sleep #Apnea, and #Osteoarthritis Outcomes Eli Lilly and Company unveiled new Phase 3 data at #ADA2026 showing that investigational triple agonist retatrutide continues to set a new benchmark in obesity medicine, demonstrating substantial weight reduction alongside meaningful improvements in Type 2 Diabetes, knee osteoarthritis pain, and obstructive sleep apnea
$50 Third-party HPLC tested with high-purity
LMD, leptomeningeal metastatic disease
J Biol Chem 280 : 1902119026 Lala S et al
The recommended daily intake is around 2.4 mcg
US$ 29.12
US$ 29.17
US$ 25.65
US$ 20.92
US$ 28.26
US$ 24.95
